{
  "ticker": "PAR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964193",
  "id": "02964193",
  "pages": 6,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0854",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l9p1lk4gs3ks.pdf",
  "summary": "### **Capital Raising Announcement Summary (Appendix 3B - Proposed Issue of Securities)**  \n\n- **Issue Structure**: Convertible Notes placement  \n- **Total Proposed Issuance**: **27,000,000 Convertible Notes** (**USD-denominated**)  \n- **Issue Price**: **USD 1.00 per Note** (~AUD 1.5281)  \n- **Maturity Date**: **1 July 2027** (zero coupon, redeemable)  \n- **Conversion Terms**:  \n  - Convertible into **PAR** ordinary shares (price based on 30 June 2025 close of **AUD $0.305**).  \n  - If fully converted, **135,275,963 shares** would be issued.  \n- **Use of Funds**: **Phase 3 clinical trials**  \n- **Key Regulatory Details**:  \n  - **7M Notes (USD 7M)** issued under 15% placement capacity (no shareholder approval).  \n  - Balance requires approval.  \n- **Broker Fees**: **4.5% fee** + **3,000,000 options** (exercise price **AUD $0.65**, expiry **30 June 2027**).  \n\n**Note**: Post-conversion dilution ~135.3M shares (subject to final terms). No escrow or underwriting.  \n\n**Prioritised for**: Liquidity impact (potential equity dilution), capital structure change (convertible debt), and funding runway (Phase 3 trial costs).",
  "usage": {
    "prompt_tokens": 2206,
    "completion_tokens": 311,
    "total_tokens": 2517,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T23:04:56.192722"
}